Trevena, Inc. TRVN
0.00 USD 0.00 (+0.00%)
Regular-session close
0.012 Day range 0.012
0.0003 52-week range 0.066
- YTD
- -95.83%
- 1 year
- -95.83%
News
defenseworld.net Trevena (NASDAQ:TRVN) Share Price Crosses Above 50-Day Moving Average – Here’s What Happened Trevena, Inc. (NASDAQ: TRVN - Get Free Report)'s share price passed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $0.01 and traded as high as…
defenseworld.net Critical Contrast: Ampio Pharmaceuticals (NYSE:AMPE) vs. Trevena (NASDAQ:TRVN) Profitability This table compares Trevena and Ampio Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Trevena N/A N/A -119.55% Ampio…
globenewswire.com Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V; and bleuacacia ltd from The Nasdaq Stock Market NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity…
zacks.com Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now After losing some value lately, a hammer chart pattern has been formed for Trevena (TRVN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate…
globenewswire.com Trevena Reports Third Quarter 2024 Results and Provides Business Update CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with…
globenewswire.com Trevena Announces Receipt of Nasdaq Delisting Notification CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with…
globenewswire.com Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones
benzinga.com What's Going On With Neurological Disease Focused Trevena On Thursday? Shares of Trevena Inc TRVN are trading lower on Thursday, with a session volume of 23.65 million, as per data from Benzinga Pro.
globenewswire.com Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization
https://www.defenseworld.net Trevena, Inc. to Post Q2 2024 Earnings of ($0.37) Per Share, HC Wainwright Forecasts (NASDAQ:TRVN) Trevena, Inc. (NASDAQ:TRVN – Free Report) – HC Wainwright dropped their Q2 2024 earnings per share (EPS) estimates for Trevena in a research report issued to clients and investors on Thursday, May…
globenewswire.com Trevena Reports First Quarter 2024 Results and Provides Business Update TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile
globenewswire.com Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies
globenewswire.com Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel…
globenewswire.com Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel…
globenewswire.com Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting -- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner
globenewswire.com Trevena Awarded OLINVYK Agreement with Premier, Inc. CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with…
globenewswire.com Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries Results from investigator-initiated RELIEVE study will be presented at the 2024 American Burn Association (ABA) Annual Meeting in Chicago from April 9th-12th Results from investigator-initiated…
seekingalpha.com Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript
globenewswire.com Trevena Reports Third Quarter 2023 Results and Provides Business Update Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement
globenewswire.com Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023 CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with…
